REMAP-CAP
A Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia
26,246
Patient randomisations
18,594
Patient randomisations with suspected or proven COVID-19
15,378
Total patients
10,482
Patients with suspected or proven COVID-19
66
Current or completed interventions in 18 Domains
298
Active Sites
A global health challenge
Respiratory tract infections are a significant cause of hospitalisation and illness world-wide, and are the leading cause of deaths from infectious disease globally.
An innovative approach to clinical research
REMAP-CAP uses an innovative trial design that is able to adapt over time to evaluate a number of treatment options simultaneously and efficiently.
An international collaboration
REMAP-CAP is a global network of leading experts, institutions and research networks. With over 250 participating institutions world-wide, REMAP-CAP is a truly global trial.
Pandemics are impossible to predict, and may spread rapidly throughout the world. The REMAP-CAP trial provides a global research platform that is able to adapt to efficiently evaluate multiple treatment options for patients who are hospitalised due to a global respiratory pandemic.
